Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 11, 2022
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
[ Wed, May 11th 2022
] - WOPRAI
Tue, May 10, 2022
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
Gena Wang Maintained (BLUE) at Sell with Decreased Target to $3 on, May 10th, 2022
Gena Wang of Barclays, Maintained "bluebird bio, Inc." (BLUE) at Sell with Decreased Target from $4 to $3 on, May 10th, 2022.
Gena has made no other calls on BLUE in the last 4 months.
There are 4 other peers that have a rating on BLUE. Out of the 4 peers that are also analyzing BLUE, 3 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $8 on, Wednesday, April 6th, 2022
- Yaron Werber of "Cowen & Co." Downgraded from Buy to Hold on, Wednesday, April 6th, 2022
- Yanan Zhu of "Wells Fargo" Maintained at Hold with Decreased Target to $8 on, Tuesday, March 8th, 2022
This is the rating of the analyst that currently disagrees with Gena
- Matthew Harrison of "Morgan Stanley" Maintained at Sell with Decreased Target to $5 on, Monday, March 7th, 2022
